o-acetyl-D,L-mandelic acid chloride | 98453-87-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: o-acetyl-D,L-mandelic acid chloride
• 英文别名: DL-0-acetylmandelic acid chloride；O-acetyl mandelic acid chloride；L-(+)-acetylmandeloyl chloride；O-acetylmandelic acid chloride；O-Acetyl-D-mandelyl chloride；acetylmandelic acid chloride；2-(2-Acetylphenyl)-2-hydroxyacetyl chloride
• CAS: 98453-87-3
• 化学式: C₁₀H₉ClO₃
• 分子量: 212.633
• InChiKey: KZKKRAVNYHSDCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  o-acetyl-D,L-mandelic acid chloride 、 2-(2-氨基乙巯基)乙醇 以 氯仿 、 水 为溶剂， 生成 N-hydroxyethylthioethyl phenyl-alpha-acetoxyacetamide
  参考文献：
  名称：

  Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use

  摘要：

  本文揭示了利用苯基α-酰氧基乙酰胺衍生物进行治疗和预防皮肤病和其他疾病症状的措施。这些化合物可能对人类的皮肤瘙痒、特应性皮炎、湿疹、牛皮癣、痤疮、干燥皮肤、头皮屑、皮肤区域的恶臭以及皮肤、关节和其他身体部位的各种疼痛和不适症状有用。苯基α-酰氧基乙酰胺衍生物包括N-乙基苯基α-乙酰氧基乙酰胺、N-苄基苯基-α-乙酰氧基乙酰胺、N-苯乙基苯基-α-乙酰氧基乙酰胺、N-苄基二苯基-α-乙酰氧基乙酰胺和N-苯乙基二苯基-α-乙酰氧基乙酰胺等。含有活性成分的配方也可用于治疗家畜（例如狗）的皮肤病或疾病和肌肉骨骼疾病，如干燥皮肤、头皮屑、湿疹、疥疮、疥疮、恶臭、关节炎或肌炎。一些苯基α-酰氧基乙酰胺衍生物可能具有镇静作用。

  公开号：

  US04518789A1
• 作为产物：
  描述：

  ortho-acetylmandelic acid 在 氯化亚砜 作用下， 生成 o-acetyl-D,L-mandelic acid chloride
  参考文献：
  名称：

  Esters of bi- and tricyclic amino alcohols and their use in

  摘要：

  公式A-O-CO-Z（I）的新化合物（其中A和Z的定义在说明书中解释）可以通过常规方法制备；它们适用于制备药物组合物的活性物质。

  公开号：

  US05654314A1

文献信息

• Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides
  申请人：ELI LILLY AND COMPANY

  公开号：EP0825164A2

  公开（公告）日：1998-02-25

  This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.

  这项发明涉及一种用于制备酰胺、碳酸酯和磺酰胺组合库的新型溶液相过程。这些库在药物发现中具有实用价值，并用于形成新型检测套件的微孔板组件。
• Phosphodiesterase inhibitors
  申请人：LES LABORATOIRES BEECHAM S.A.

  公开号：EP0381374A1

  公开（公告）日：1990-08-08

  A compound of formula (I), or a pharmaceutically acceptable salt thereof: in which, R₁ is hydrogen, C₁₋₆ alkyl or CH₂OR₆; R₂ is hydrogen or C₁₋₆ alkyl; R₃ is hydrogen or C₁₋₆ alkyl; each of W and Z, which are different, represents -CR₄R₅- or -(CRxRy)n-, in which, R₄ is hydrogen, C₁₋₃ alkyl, C₁₋₃ alkylthio, C₁₋₃ alkoxy or C₁₋₆ alkyl phenyl; R₅ is C₁₋₃ alkyl, C₁₋₃ alkylthio, C₁₋₃ alkoxy, phenyl, substituted phenyl, C₃₋₆ cycloalkyl, phenylthio, C₁₋₆ alkyl phenyl, halo-substituted benzyl, or heteroaryl; or together R₄ and R₅ form a 3 to 6 membered carbocyclic ring, or a heterocyclic ring containing one or two ring oxygen, nitrogen or sulphur atoms, or R₄ and R₅ together form an oxo or methylene group; each of Rx and Ry is hydrogen or C₁₋₃ alkyl; n is zero or 1; R₆ is phenyl substituted aminocarbonyl, C₁₋₆ alkoxy carbonyl-C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, phenyl, C₃₋₆ cycloalkylcarbonyl, C₃₋₆ cycloalkylcarbonyl-C₁₋₆ alkyl, C₃₋₆ cycloalkyl C₁₋₆ alkyl; C₁₋₆ alkylthiocarbonyl; halo-substituted C₁₋₆ alkoxycarbonyl; C₁₋₆ alkoxy C₁₋₆ alkyleneoxycarbonyl; C₁₋₆ alkylthio C₁₋₆ alkyleneoxycarbonyl; C₁₋₆ alkoxythiocarbonyl; C₃₋₆ cycloalkyloxycarbonyl; cyano substituted C₁₋₆ alkoxycarbonyl; di-C₁₋₆ alkylphosphonate; C₁₋₆ alkenyloxycarbonyl; or R₆ is hydrogen when R₅ is phenyl, C₃₋₆ cycloalkyl, phenylthio, C₁₋₆ alkylphenyl or halo-substituted benzyl; R₆ is benzoyl or aminobenzoyl when R₄ and R₅ form a C₃₋₆ cycloalkyl ring; R₇ is hydrogen, C₁₋₆ alkyl or halogen; X is oxygen or sulphur; and A is sulphur, oxygen or -NH-, is useful for the treatment of heart disease.

  式（I）的化合物，或其药学上可接受的盐：其中，R₁为氢，C₁₋₆烷基或CH₂OR₆；R₂为氢或C₁₋₆烷基；R₃为氢或C₁₋₆烷基；W和Z中的每一个，它们不同，代表-CR₄R₅-或-(CRxRy)n-，其中，R₄为氢，C₁₋₃烷基，C₁₋₃烷基硫，C₁₋₃烷氧基或C₁₋₆烷基苯基；R₅为C₁₋₃烷基，C₁₋₃烷基硫，C₁₋₃烷氧基，苯基，取代苯基，C₃₋₆环烷基，苯硫基，C₁₋₆烷基苯基，卤代苄基或杂环烷基；或者R₄和R₅一起形成3到6成员的碳环，或者含有一个或两个环氧原子、氮原子或硫原子的杂环；或者R₄和R₅一起形成氧或亚甲基基团；Rx和Ry中的每一个为氢或C₁₋₃烷基；n为零或1；R₆为苯基取代氨基甲酰基，C₁₋₆烷氧基甲酰基-C₁₋₆烷基，苯基-C₁₋₆烷基，苯基，C₃₋₆环烷基甲酰基，C₃₋₆环烷基甲酰基-C₁₋₆烷基，C₃₋₆环烷基C₁₋₆烷基；C₁₋₆烷基硫代甲酰基；卤代C₁₋₆烷氧基甲酰基；C₁₋₆烷氧基-C₁₋₆烷基氧基甲酰基；C₁₋₆烷基硫基-C₁₋₆烷基氧基甲酰基；C₁₋₆烷氧基硫代甲酰基；C₃₋₆环烷氧基甲酰基；氰基取代C₁₋₆烷氧基甲酰基；二C₁₋₆烷基膦酸酯；C₁₋₆烯氧基甲酰基；或者当R₅为苯基，C₃₋₆环烷基，苯硫基，C₁₋₆烷基苯基或卤代苄基时，R₆为氢；当R₄和R₅形成C₃₋₆环烷基环时，R₆为苯甲酰基或氨基苯甲酰基；R₇为氢，C₁₋₆烷基或卤素；X为氧或硫；A为硫，氧或-NH-，用于治疗心脏病。
• 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US06174884B1

  公开（公告）日：2001-01-16

  The 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives are prepared by fusing the pyrimidone heterocycle with the suitably substituted pyrazoles. The compounds are suitable as active compounds in medicaments, in particular in medicaments for the treatment of cardiovascular and cerebrovascular diseases, diseases of the peripheral blood vessels and diseases of the urogenital tract.

  1,5-二氢吡唑并[3,4-d]-嘧啶酮衍生物是通过将嘧啶酮杂环与适当取代的吡唑融合而制备的。这些化合物适用于作为药物中的活性成分，特别是用于治疗心血管和脑血管疾病、外周血管疾病以及泌尿生殖道疾病的药物。
• [EN] ASYMMETRIC CYCLIC DIESTER COMPOUNDS<br/>[FR] COMPOSÉS DIESTERS CYCLIQUES ASYMÉTRIQUES
  申请人：FERRO CORP

  公开号：WO2011071674A1

  公开（公告）日：2011-06-16

  Compounds useful as plasticizers and the synthesis thereof are disclosed. In general, the invention includes mixed alkyl/aryl asymmetric cyclic diesters where the aryl and alkyl ester moieties are attached to a cyclic structure at vicinal carbons. The invention also includes synthetic processes of making such compounds. Blends of these asymmetric cyclic diesters with other plasticizers are demonstrated to be of use in plasticizing polymers.

  本文披露了作为增塑剂有用的化合物及其合成方法。一般来说，该发明包括混合烷基/芳基不对称环状二酯，其中芳基和烷基酯基连接到环状结构的邻位碳上。该发明还包括制备这类化合物的合成过程。这些不对称环状二酯与其他增塑剂的混合物被证明在增塑聚合物中具有用途。
• Modulators of TNF-alpha signaling
  申请人：Genzyme Corporation

  公开号：US20020119988A1

  公开（公告）日：2002-08-29

  The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition. The compounds can be represented by the following structural formulas: 1

  本发明提供了一种调节TNF-α信号的化合物，以及这些化合物的使用方法，用于治疗患有TNF-α介导疾病的患者。这些化合物可以用以下结构式表示：1